Akero Therapeutics SEC Filings

Akero Therapeutics agreed to be acquired by Novo Nordisk through a merger that will make Akero a wholly owned subsidiary of Novo Nordisk. The transaction includes cash consideration and a contingent value right (CVR) structure that awards one CVR per share and ties payments to specified regulatory and commercial milestones; in-the-money stock options will be cashed out plus converted into CVRs on a per-share basis. The merger is subject to customary closing conditions including antitrust and foreign investment clearances and approval by holders of a majority of Akero's common stock. Akero will file a proxy statement with additional details and warns that CVRs may yield no payment if milestones are not met and that regulatory approvals, competing offers, or other closing conditions could prevent or delay completion.

Deep Track entities and individual David Kroin reported ownership of 4,400,000 shares of Akero Therapeutics common stock, representing 5.50% of the outstanding shares based on 79,988,975 shares outstanding as of July 31, 2025. The filing is a joint Schedule 13G dated October 7, 2025, showing shared voting and dispositive power over the 4,400,000 shares and no sole voting or dispositive power. The reporting parties are Deep Track Capital, LP (Delaware), Deep Track Biotechnology Master Fund, Ltd. (Cayman Islands) and David Kroin (U.S.).

The statement certifies the position was not acquired to change or influence control of the issuer and includes a joint filing agreement assigning responsibility for future amendments. The ownership percentage and shared control are material to investors because the stake exceeds the 5% reporting threshold and is publicly disclosed under SEC rules.

Akero Therapeutics, Inc. (AKRO) Form 144 shows an insider sale notice for 56,369 shares of common stock to be sold through J.P. Morgan Securities LLC on 10/07/2025 with an aggregate market value of $2,595,229. The filing states these shares were acquired the same day via a stock option exercise and paid as compensation. The filer also reported two prior open-market sales this year: 12,500 shares on 08/05/2025 for $616,299 and 12,500 shares on 09/08/2025 for $552,135. The form includes the required representation that the seller does not possess undisclosed material adverse information and identifies the executing broker and the number of shares outstanding (79,988,975), enabling investors to see the scale of the disclosed sale relative to the company’s share count.

Jonathan Young, Chief Operating Officer of Akero Therapeutics, Inc. (AKRO), reported multiple transactions on 10/01/2025 under a Rule 10b5-1 plan. He acquired 12,500 stock options at an exercise price of $21.10 and exercised options that resulted in ownership of 82,482 common shares in total. On the same date he sold 12,500 common shares via a market sale at a weighted-average price of $21.10 (option acquisition) and separately sold 8,299 shares at a weighted-average price of $47.644 and 4,201 shares at a weighted-average price of $47.984. Following the reported transactions, he directly beneficially owned 196,898 shares. He also holds indirect interests of 20,000 shares each through three irrevocable trusts for his children, which he disclaims as beneficial ownership.

Akero Therapeutics insider transaction summary: Chief Scientific Officer Timothy Rolph executed multiple transactions on 09/08/2025 under a Rule 10b5-1 trading plan. The Form 4 reports sales totaling 12,500 common shares (12,466 shares at a weighted-average price of $44.169 and 34 shares at $44.875) and three option-related acquisitions recorded as M(1) exchanges: 7,044 option rights with $21.09 strike, 5,161 option rights with $6.364 strike, and 295 option rights with $28.35 strike. Following the transactions, Rolph beneficially owned 167,124 common shares (direct). The filing notes the options are vested and exercisable and that the trades were effected pursuant to a 10b5-1 plan dated August 12, 2024.

Akero Therapeutics (AKRO) Form 144 filing reports a proposed sale of Common Stock by an insider. The notice lists a broker, J.P. Morgan Securities, and an approximate aggregate market value of the proposed sale at $4,015,800 for 90,000 shares, with an approximate sale date of 09/10/2025 on NASDAQ. The filing details the insider's acquisition history: 478 shares from an ESPP on 06/28/2024, 14,581 shares from RSU vesting on 03/09/2023, and 74,941 shares from a stock option exercise on 09/10/2025. It also discloses recent dispositions: 30,000 shares sold on 07/10/2025 for $1,534,895 and 30,000 shares sold on 08/11/2025 for $1,457,589. The filer represents no undisclosed material adverse information.

Akero Therapeutics insider transactions on 09/02/2025 show Jonathan Young, Chief Operating Officer, exercised stock options and sold an equal number of shares under a Rule 10b5-1 plan. The filing reports an exercise/acquisition of 12,500 shares at $21.10 and sales totaling 12,500 shares executed at weighted-average prices of $45.776, $47.136 and $47.58. After these transactions Mr. Young beneficially owned 197,484 shares direct and additionally has three irrevocable trusts holding 20,000 shares each, which he disclaims as beneficial ownership. The transactions were effected pursuant to a 10b5-1 trading plan dated April 29, 2025.

Scott A. Gangloff, Chief Technology Officer of Akero Therapeutics (AKRO), reported a securities transaction dated 08/15/2025. The filing shows an acquisition of 2,600 shares/options with a reported price of $19.62, increasing the reporting person’s beneficial ownership to 26,351 shares following the transaction.

The filing also discloses a derivative position: a stock option with a $19.62 exercise price covering 20,384 underlying common shares, of which 17,784 derivative securities are reported as beneficially owned. The option vests 25% on April 29, 2025, with the balance vesting in 36 equal monthly installments, subject to continued service. The form is signed by an attorney-in-fact on 08/19/2025.